215 related articles for article (PubMed ID: 22743087)
1. Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.
Qian W; Park JE; Liu F; Lee KS; Burke TR
Bioorg Med Chem; 2013 Jul; 21(14):3996-4003. PubMed ID: 22743087
[TBL] [Abstract][Full Text] [Related]
2. Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.
Hymel D; Burke TR
ChemMedChem; 2017 Feb; 12(3):202-206. PubMed ID: 27992122
[TBL] [Abstract][Full Text] [Related]
3. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.
Qian WJ; Park JE; Lim D; Lai CC; Kelley JA; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
Biopolymers; 2014 Nov; 102(6):444-55. PubMed ID: 25283071
[TBL] [Abstract][Full Text] [Related]
4. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.
Qian WJ; Park JE; Lim D; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
Chem Biol; 2013 Oct; 20(10):1255-64. PubMed ID: 24120332
[TBL] [Abstract][Full Text] [Related]
5. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).
Qian WJ; Park JE; Lee KS; Burke TR
Bioorg Med Chem Lett; 2012 Dec; 22(24):7306-8. PubMed ID: 23159568
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic.
Yin Z; Song Y; Rehse PH
ACS Chem Biol; 2013 Feb; 8(2):303-8. PubMed ID: 23135290
[TBL] [Abstract][Full Text] [Related]
7. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
8. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
[TBL] [Abstract][Full Text] [Related]
10. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.
Liu F; Park JE; Qian WJ; Lim D; Scharow A; Berg T; Yaffe MB; Lee KS; Burke TR
ACS Chem Biol; 2012 May; 7(5):805-10. PubMed ID: 22292814
[TBL] [Abstract][Full Text] [Related]
11. Polo-box domain: a versatile mediator of polo-like kinase function.
Park JE; Soung NK; Johmura Y; Kang YH; Liao C; Lee KH; Park CH; Nicklaus MC; Lee KS
Cell Mol Life Sci; 2010 Jun; 67(12):1957-70. PubMed ID: 20148280
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
15. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of the polo-box domain of human Polo-like kinase 2.
Kim JH; Ku B; Lee KS; Kim SJ
Proteins; 2015 Jul; 83(7):1201-8. PubMed ID: 25846005
[TBL] [Abstract][Full Text] [Related]
17. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
[TBL] [Abstract][Full Text] [Related]
18. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks.
Mao XL; Wang KF; Zhu F; Pan ZH; Wu GM; Zhu HY
Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535
[TBL] [Abstract][Full Text] [Related]
19. Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.
Murugan RN; Ahn M; Lee WC; Kim HY; Song JH; Cheong C; Hwang E; Seo JH; Shin SY; Choi SH; Park JE; Bang JK
PLoS One; 2013; 8(11):e80043. PubMed ID: 24223211
[TBL] [Abstract][Full Text] [Related]
20. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.
García-Alvarez B; de Cárcer G; Ibañez S; Bragado-Nilsson E; Montoya G
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3107-12. PubMed ID: 17307877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
